TY - JOUR
T1 - Etiology of super-enhancer reprogramming and activation in cancer
AU - Zhou, Royce W.
AU - Parsons, Ramon E.
N1 - Publisher Copyright:
© 2023, The Author(s).
PY - 2023/12
Y1 - 2023/12
N2 - Super-enhancers are large, densely concentrated swaths of enhancers that regulate genes critical for cell identity. Tumorigenesis is accompanied by changes in the super-enhancer landscape. These aberrant super-enhancers commonly form to activate proto-oncogenes, or other genes upon which cancer cells depend, that initiate tumorigenesis, promote tumor proliferation, and increase the fitness of cancer cells to survive in the tumor microenvironment. These include well-recognized master regulators of proliferation in the setting of cancer, such as the transcription factor MYC which is under the control of numerous super-enhancers gained in cancer compared to normal tissues. This Review will cover the expanding cell-intrinsic and cell-extrinsic etiology of these super-enhancer changes in cancer, including somatic mutations, copy number variation, fusion events, extrachromosomal DNA, and 3D chromatin architecture, as well as those activated by inflammation, extra-cellular signaling, and the tumor microenvironment.
AB - Super-enhancers are large, densely concentrated swaths of enhancers that regulate genes critical for cell identity. Tumorigenesis is accompanied by changes in the super-enhancer landscape. These aberrant super-enhancers commonly form to activate proto-oncogenes, or other genes upon which cancer cells depend, that initiate tumorigenesis, promote tumor proliferation, and increase the fitness of cancer cells to survive in the tumor microenvironment. These include well-recognized master regulators of proliferation in the setting of cancer, such as the transcription factor MYC which is under the control of numerous super-enhancers gained in cancer compared to normal tissues. This Review will cover the expanding cell-intrinsic and cell-extrinsic etiology of these super-enhancer changes in cancer, including somatic mutations, copy number variation, fusion events, extrachromosomal DNA, and 3D chromatin architecture, as well as those activated by inflammation, extra-cellular signaling, and the tumor microenvironment.
KW - Cancer
KW - Enhancers
KW - Extrachromosomal DNA
KW - Inflammation
KW - Insulators
KW - Non-coding mutations
KW - Phase separation
KW - Super-enhancers
KW - Therapeutic resistance
KW - Topologically associated domain
KW - Tumor microenvironment
UR - http://www.scopus.com/inward/record.url?scp=85164265099&partnerID=8YFLogxK
U2 - 10.1186/s13072-023-00502-w
DO - 10.1186/s13072-023-00502-w
M3 - Review article
C2 - 37415185
AN - SCOPUS:85164265099
SN - 1756-8935
VL - 16
JO - Epigenetics and Chromatin
JF - Epigenetics and Chromatin
IS - 1
M1 - 29
ER -